2. Protein Tyrosine Kinase/RTK Immunology/Inflammation Apoptosis
  3. Btk Pyroptosis
  4. BTK-IN-15

BTK-IN-15 (compound 42) 是一种新型的布鲁顿酪氨酸激酶 (BTK) 抑制剂，具有良好口服活性。BTK-IN-15 抑制 BTK，IC50 为 0.7 nM，并具有良好的激酶选择性和抗肿瘤活性，能诱导癌细胞凋亡 (apoptosis)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK-IN-15 Chemical Structure

BTK-IN-15 Chemical Structure

CAS No. : 2820426-92-2

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

BTK-IN-15 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

BTK-IN-15 (compound 42) is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits BTK with an IC50 value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis[1].

IC50 & Target

IC50: 0.7 nM (BTK)[1]
体外研究
(In Vitro)

BTK inhibition is an effective approach against B-cell malignancies[1].
BTK-IN-15 (compound 42) demonstrates inhibitory against TMD8 with an IC50 value of 2.6 nM[1].
BTK-IN-15 (1 μM; 1 h) displays significant selectivity to BTK over EGFR kinase with 0.05% and 44% of the control, respectively[1].
BTK-IN-15 (0-1 mM; 72 h) exerts potent anti-proliferative activity against a human mantle cell lymphoma cell line (REC-1) with an IC50 value of 1.7 nM[1].
BTK-IN-15 (0-1 mM; 2 h) inhibits BTK auto-phosphorylation with an IC50 value of 1.49 nM[1].
BTK-IN-15 (0-100 nM; 48 h) arrests cell cycle at G1 phase and (0-1 mM; 72 h) induces apoptosis in TMD8[1].
BTK-IN-15 shows low hERG channel activity (IC50=4.38 μM), indicating low cardiotoxicity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

BTK-IN-15 相关抗体:

Western Blot Analysis[1]

Cell Line: B-cell lymphoma (DLBCL) TMD8 cancer cells
Concentration: 0, 0.15, 0.46, 1.37, 4.12, 12.35, 37.04, 111, 333, 1000 nM
Incubation Time: 2 hours
Result: Inhibited BTK auto-phosphorylation at the Tyr223 site with an IC50 value of 1.49 nM.

Cell Cycle Analysis[1]

Cell Line: B-cell lymphoma (DLBCL) TMD8 cancer cells
Concentration: 0, 10, 100 nM
Incubation Time: 48 hours
Result: Arrested cell cycle progression at G1 phase in a dose-dependent manner, the percentage of cells in the G0/G1 phase increased from 33.0 to 63.0% with a dose range of 1-100 nM.

Apoptosis Analysis[1]

Cell Line: B-cell lymphoma (DLBCL) TMD8 cancer cells
Concentration: 0, 10, 100, 1000 nM
Incubation Time: 72 hours
Result: Induced apoptosis of TMD8 cells in a weakly triggered concentration-dependent manner, with the apoptosis cell values of 19% (10 nM), 25.2% (100 nM), and 31.4% (1000 nM), respectively.
体内研究
(In Vivo)

BTK-IN-15 (compound 42) (12.5-50 mg/kg; p.o.; twice daily; 21 d) inhibits tumor growth (TGI = 104%) at a dosage of 50 mg/kg in mice[1].
BTK-IN-15 (300, 400, 500 mg/kg; p.o.; twice daily; 14 d) has biological safety and displays no affect against body weight in mice compared with control[1].
BTK-IN-15 (10 mg/kg; p.o.) shows a high oral bioavailability of 40.98% in mice[1].
Pharmacokinetics of BTK-IN-15 in Mice[1]

Route Dose (mg/kg) Tmax (h) Cmax (ng/mL) AUC(0-t) (h•ng/mL) AUC(0-∞) (h•ng/mL) T1/2 (h) Vz (L/kg) CL (L/h/kg) F (%)
i.v. 2 0.03 2245.39 1471.35 718.33 0.67 2.79 2.87 40.98
p.o. 10 0.39 1441.59 718.33 1472.06 0.59

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CB-17 SCID nude mice with TMD8 xenograft model[1]
Dosage: 12.5 mg/kg, 25 mg/kg, and 50 mg/kg
Administration: Oral gavage; twice daily; 21 days
Result: Inhibited tumor growth at a dosage of 50 mg/kg and reduced tumor volume after 21 days with a TGI of 104%.
Reduced the content of white blood cells, lymphocytes and monocytes, while showed no effect on red blood cell and platelets.
Animal Model: ICR mice (acclimation for 5 days, 18-20 g)[1]
Dosage: 300, 400, 500 mg/kg
Administration: Oral gavage; 14 days
Result: Demonstrated no affect against body weight in mice compared with control.
分子量

481.52

Formula

C28H24FN5O2
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

BTK-IN-15 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BTK-IN-152820426-92-2BtkPyroptosisBruton tyrosine kinasekinase selectivityB-celllymphomaspyrrolopyrimidinelow toxicityantitumor activityoral absorptionantiproliferativeInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
BTK-IN-15
目录号：
HY-150752
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z